Navigation Links
CTD Holdings, Inc. Announces Refinancing of Long Term Debt
Date:8/8/2013

Alachua, Florida (PRWEB) August 08, 2013

CTD Holdings, Inc. (OTCQB:CTDH) closed on a series of loans through Regions Bank that refinances its existing indebtedness into three notes at favorable interest rates. The three notes consist of: a Mortgage on the company's Alachua, FL property of $578,998 with an interest rate of 3.99%; an Equipment Loan of $295,890 secured by a lien on the company's manufacturing equipment with an interest rate of 3.99%; and a Line of Credit for $100,000 with an interest rate of prime plus 1.8% currently 5.05%. A complete description of the loan package is found in the SEC Form 8K filed July 26, 2013.

This new lending facility with Regions Bank positions the company for continued future growth by improving monthly cash flow, reducing the effective interest rate on the Company’s debt by more than 2%, and extending the maturity of the debt. Regions Bank is a strong banking partner able to meet the Company’s larger and more complicated banking service needs as it grows.

“We are delighted to establish a primary banking relationship with Regions Bank.” stated CTD Holdings President, Dr. Jeffrey Tate, “Regions is well positioned to provide the level of service and banking support our Company will need as we continue to grow.”

As part of the loan package, CTD Holdings has agreed to make Regions Bank home for its primary operation accounts.

“The improved cash flow and reduced borrowing costs mean the Company is now better positioned to invest in new products and sales activities.” said CTD Holdings Director of Operations, Mr. Kevin Strattan.

CTD Holdings is currently upgrading its internet eCommerce site and developing ultra pure products for cosmetic, cell culture and pharmaceutical applications.

About the Company: 

The CTD Holdings, Inc. Family of Companies manufacture and market Trappsol and Aquaplex cyclodextrins and cyclodextrin complexes for food, nutrition and pharmaceutical markets. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of pharmaceutical grade Aquaplex cyclodextrin complexes. The companies offer a wide variety of cyclodextrin related manufacturing services to its worldwide customers; including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's website.

Safe Harbor Statement:

This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Read the full story at http://www.prweb.com/releases/CTDHoldingsInc/LoanPackage8K/prweb11002183.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
2. Innophos Holdings, Inc. Reports First Quarter 2012 Results
3. China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 2012
4. Inclinix-PMG Holdings, Inc. Announces Executive Management Changes
5. Organovo Holdings, Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
6. Aveka Nutra Processing proudly begins producing products from Z Trim Holdings, Inc.
7. Organovo Holdings, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
8. Z Trim Holdings, Inc. adds non-GMO corn products to its product line
9. Z Trim Holdings, Inc. Enters into Joint Development Agreement with Drilling Fluids Company
10. Z Trim Holdings, Inc. Records First Non-GMO Corn Sales
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program Committee ... honoring scientists who have made outstanding contributions to analytical chemistry and applied ... the world’s leading conference and exposition for laboratory science, which will be held ...
Breaking Biology Technology:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
Breaking Biology News(10 mins):